RenovoRx, Inc. (RNXT)
0.92
+0.03
(+3.29%)
USD |
NASDAQ |
Jun 18, 16:00
0.9206
0.00 (0.00%)
After-Hours: 20:00
RenovoRx Gross Profit Margin (Quarterly) : 85.08% for March 31, 2026
Gross Profit Margin (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Gross Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2026 | 85.08% |
| December 31, 2025 | 88.24% |
| September 30, 2025 | 80.08% |
| Date | Value |
|---|---|
| June 30, 2025 | 63.98% |
| March 31, 2025 | 52.28% |
| December 31, 2024 | 0.00% |
Gross Profit Margin Definition
Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.
Gross Profit Margin (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Gross Profit Margin (Quarterly) Benchmarks
| Cytokinetics, Inc. | 69.36% |
| ACADIA Pharmaceuticals, Inc. | 90.75% |
| Alnylam Pharmaceuticals, Inc. | 81.91% |
| Anika Therapeutics, Inc. | 64.15% |
| Savara, Inc. | -- |
Gross Profit Margin (Quarterly) Related Metrics
| Return on Equity | -126.3% |
| Return on Assets | -97.42% |
| Return on Invested Capital | -123.3% |
| Profit Margin (Quarterly) | -625.4% |
| Operating Margin (Quarterly) | -616.2% |
| Return on Net Operating Assets | -1.16K% |